U.S. Liver Cancer Diagnostics Market To Reach $4.37 Billion By 2030

U.S. Liver Cancer Diagnostics Market Growth & Trends

The U.S. liver cancer diagnostics market is anticipated to reach USD 4.37 billion by 2030, exhibiting a CAGR of 4.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. This growth is attributable to the increasing prevalence of liver cancer, rising prevalence of risk factors for liver cancer, and technological advancements. The significant prevalence of liver cancer in the country highlights the need for its prevention, detection, and treatment. For instance, liver and intrahepatic bile duct cancer accounted for 2.2% of all new cancer cases in 2022.

Moreover, the growing number of government programs and collaborative efforts to transform cancer prevention, detection, treatment, and research in the country through substantial investments, data-driven approaches, and nationwide collaborations are further expected to propel market growth. For instance, the Translational Liver Cancer (TLC) Consortium, established by the National Cancer Institute’s (NCI) Division of Cancer Prevention, aims to advance translational research specifically focused on improving surveillance, early detection, and risk stratification of liver cancer.

The Cancer Moonshot initiative initiated in February 2022 highlights the importance of collaborative efforts in advancing cancer research, treatment, and patient care. A significant investment of USD 240 million in the Cancer Moonshot supports new ways to prevent, detect, treat, and survive cancer. This funding is likely channeled through the Advanced Research Projects Agency for Health (ARPA-H) to researchers and innovators working on cancer-related projects. The investment includes initiatives such as developing tools for early cancer detection, innovative approaches for visualizing cancer cells during surgery, novel treatment methods like using bacteria to target cancer cells and designing devices for more effective tumor treatment.

 Request a free sample copy or view report summary: U.S. Liver Cancer Diagnostics Market Report

U.S. Liver Cancer Diagnostics Market Report Highlights

• In terms of end-use, the hospitals and diagnostic laboratories segment dominated the market with the highest share of around 50%. This high share is attributable to the significant presence of hospitals across the country.

• Based on test type, the molecular markers segment is expected to grow at the fastest CAGR of 9.9% over the forecast period owing to the recent developments in the discovery of novel biomarkers for cancer research and diagnosis.

• The laboratory tests segment accounted for the largest revenue share of around 40% in 2023 due to their ability to detect biomarkers, facilitate early detection, and provide prognostic information in cancer diagnosis.

• In Jan 2023, Amy Kim and her team from Johns Hopkins Medicine developed a new screening test for liver cancer, which uses urine to isolate complementary tumor DNA for cancer detection.

U.S. Liver Cancer Diagnostics Market Segmentation

Grand View Research has segmented the U.S. liver cancer diagnostics market on the basis of test type, end-use, and region.

U.S. Liver Cancer Diagnostics Test Type Outlook (Revenue, USD Million, 2018 - 2030)

• Laboratory Tests

  • Biomarkers

    • Oncofetal and Glycoprotein Antigens

    • Enzymes and Isoenzymes

    • Growth Factors and Receptors

    • Molecular Markers

    • Pathological Biomarkers

  • Blood Tests

• Imaging

• Endoscopy

• Biopsy

• Others

U.S. Liver Cancer Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals & Diagnostic Laboratories

• Academic & Research Institutes

• Pharmaceutical & CRO Laboratories

U.S. Liver Cancer Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• West

• Midwest

• Northeast

• Southwest

• Southeast

List of Key Players in the U.S. Liver Cancer Diagnostics Market

• Abbott Laboratories

• Guardant Health

• Thermo Fisher Scientific, Inc.

• Illumina, Inc.

• F. Hoffmann-La Roche Ltd.

• Qiagen N.V.

• Siemens Healthineers

• Becton, Dickinson & Company

• Epigenomics AG

• Koninklijke Philips N.V.

• FUJIFILM Healthcare Americas Corporation